Status:

RECRUITING

HemoSphere Alta Study

Lead Sponsor:

Edwards Lifesciences

Conditions:

Hemodynamic Instability

Eligibility:

All Genders

18+ years

Brief Summary

A prospective, non-randomized single arm study using the HemoSphere Alta Advanced Monitoring Platform and associated devices in adult subjects. Data collected from enrolled study subjects will be used...

Eligibility Criteria

Inclusion

  • Signed informed consent
  • Age ≥ 18 years
  • Planned monitoring with a pulmonary artery catheter
  • Patient scheduled to undergo cardiac or liver transplant surgery lasting \> 2 hours
  • Additional criteria for Sub-Cohort A (RVF)
  • Possible Right Ventricular Dysfunction/Failure based on pre-operative assessment of previous Transthoracic Echocardiogram (TTE)
  • Planned Transesophageal Echocardiogram (TEE) assessment during the operative procedure
  • Additional criteria for Sub-Cohort B (CAI)
  • Age ≥ 45 years
  • Planned cardiac surgery with Cardiopulmonary Bypass (CPB)
  • Ability to place ForeSight IQ and Acumen IQ sensors during the operative monitoring period
  • High risk for cerebral vascular disease, defined as: a history of hypertension, pulse pressure \> 60 mmHg, diabetes, stroke, transient ischemic attack, carotid bruit, tobacco smoking, or peripheral vascular disease

Exclusion

  • Inability to provide informed consent
  • Pregnancy as confirmed per EMR
  • Patients deemed not suitable for the study at the discretion of the Investigator
  • Participation in another study that clinically interferes with the current study
  • Additional exclusion criteria for Sub-Cohort A
  • Presence of left bundle branch block
  • Presence of current/recurrent sepsis
  • Presence of hypercoagulability, as identified in the patient's past medical history and preoperative evaluation
  • Structural abnormality, including congenital heart defects, of the right ventricle
  • Additional exclusion criteria for Sub-Cohort B a. Surgery for congenital heart defect

Key Trial Info

Start Date :

October 14 2025

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

December 1 2026

Estimated Enrollment :

100 Patients enrolled

Trial Details

Trial ID

NCT07148323

Start Date

October 14 2025

End Date

December 1 2026

Last Update

November 10 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

University of Rochester Medical Center

Rochester, New York, United States, 14620